Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors
- 1 July 1987
- journal article
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 1 (2) , 97-119
- https://doi.org/10.1007/bf01676955
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Strategic approaches to drug design. I. An integrated software framework for molecular modellingJournal of Computer-Aided Molecular Design, 1987
- Cardiotonic agents. 4. Synthesis and biological evaluation of N-substituted 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones: rigid structures derived from CI-930 and analogsJournal of Medicinal Chemistry, 1986
- Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinoneJournal of Medicinal Chemistry, 1986
- Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agentsJournal of Medicinal Chemistry, 1985
- A New Generation of Phosphodiesterase Inhibitors: Multiple Molecular Forms of Phosphodiesterase and the Potential for Drug SelectivityJournal of Medicinal Chemistry, 1985
- Functional group contributions to drug-receptor interactionsJournal of Medicinal Chemistry, 1984
- Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failureJournal of Medicinal Chemistry, 1984
- Identification and properties of cyclic nucleotide phosphodiesterasesMolecular and Cellular Endocrinology, 1982
- Conformations of cyclic 3′,5′-nucleotides. Effect of the base on the syn-anti conformer distributionBiochemical and Biophysical Research Communications, 1974
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973